Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05953441
Other study ID # NUS-IRB-2022-202
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 8, 2022
Est. completion date November 13, 2022

Study information

Verified date July 2023
Source National University of Singapore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to compare the effectiveness of Artificial Intelligence virtual doctor with human-controlled virtual doctor avatars on nursing students' sepsis care and interprofessional communication.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date November 13, 2022
Est. primary completion date October 26, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. All Year 3 NUS nursing students in Academic Year 2022 2. Individuals 20 years old and above; and 3. Consent to be video and/or audio-recorded Exclusion Criteria: 1. Year 1, 2 and 4 NUS nursing students; 2. Incapable of giving informed consent; 3. Unable to understand and/or speak in English language; 4. Have visual, speech, and/or hearing impairment; and 5. Do not agree to be video and/or audio-recorded.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
AI-powered doctor
AI-powered virtual doctor
Human-controlled doctor avatar
Virtual doctor avatar controlled by the medical student.

Locations

Country Name City State
Singapore Alice Lee Centre for Nursing Studies Singapore

Sponsors (2)

Lead Sponsor Collaborator
National University of Singapore Ministry of Education, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in Sepsis Knowledge on the 18-item sepsis knowledge test immediately after interventions. The 8-item communication knowledge and 18-item sepsis knowledge tests were developed and content validated by a multidisciplinary team comprising a medical doctor, an advanced practice nurse, and nursing academics. Baseline and immediately after 2-hour VRS
Secondary Change from Baseline in Team Communication Knowledge on the 8-item communication knowledge test immediately after interventions. The 8-item communication knowledge and 18-item sepsis knowledge tests were developed and content validated by a multidisciplinary team comprising a medical doctor, an advanced practice nurse, and nursing academics. Baseline and immediately after 2-hour VRS
Secondary Change from Baseline in Team Communication Self-Efficacy on the 6-item Patient Clinical Information Exchange and Interprofessional Communication Self-Efficacy Scale immediately after interventions. The Patient Clinical Information Exchange and Interprofessional Communication Self-Efficacy Scale is a validated and self-reported instrument using a 0-100 Likert scale, which measures participants' perceptions of self-efficacy in team communication based on the ISBAR communication strategy. Baseline and immediately after 2-hour VRS
Secondary Sepsis Care Performance through a 15-minute video-recorded simulation-based assessment within 2 weeks of postintervention. 2 independent raters used the validated RAPIDS (Rescuing A Patient In Deteriorating Situation) tool to measure nurses' simulation performance in assessing and managing a deteriorating patient. Within 2 weeks of postintervention.
Secondary Team Communication Performance through a 15-minute video-recorded simulation-based assessment within 2 weeks of postintervention. 2 independent raters used a validated 9-item team communication scale to assess nurses' simulation performance in communicating with doctor using the TeamSTEPPS communication strategies. Within 2 weeks of postintervention.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3